Jessica Lee1, Arun Singh2, Siraj M Ali1, Douglas I Lin3, Samuel J Klempner4. 1. Foundation Medicine, Cambridge, MA, USA. 2. Department of Medical Oncology, University of California Los Angeles, Los Angeles, CA, USA. 3. Beth Israel Deaconess Medical Center, Boston, MA, USA. 4. The Angeles Clinic and Research Institute, Los Angeles, CA, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. sklempner@theangelesclinic.org.
Abstract
OBJECTIVE: We report a female patient diagnosed with a leiomyosarcoma and who harbored a druggable target as identified by comprehensive genomic profiling in the course of clinical care. CASE REPORT: The patient progressed five years after curative intent surgery and adjuvant treatment. After failure of multiple lines of chemotherapy,she was enrolled in a trial of an ALK inhibitor based on comprehensive genomic profiling (CGP) identifying an TNS1-ALK fusion. CONCLUSION: In this case, identification of the ALK kinase fusion permitted enrollment in a matched mechanism driven clinical trial after exhausting standard of care treatment options. CGP raises the possibility of uterine inflammatory myofibroblastic tumor as an alternative diagnosisto leiomyosarcoma, highlighting the complementary role of CGP beyond immunohistochemical analyses.
OBJECTIVE: We report a female patient diagnosed with a leiomyosarcoma and who harbored a druggable target as identified by comprehensive genomic profiling in the course of clinical care. CASE REPORT: The patient progressed five years after curative intent surgery and adjuvant treatment. After failure of multiple lines of chemotherapy,she was enrolled in a trial of an ALK inhibitor based on comprehensive genomic profiling (CGP) identifying an TNS1-ALK fusion. CONCLUSION: In this case, identification of the ALK kinase fusion permitted enrollment in a matched mechanism driven clinical trial after exhausting standard of care treatment options. CGP raises the possibility of uterine inflammatory myofibroblastic tumor as an alternative diagnosisto leiomyosarcoma, highlighting the complementary role of CGP beyond immunohistochemical analyses.
Authors: Mrinal M Gounder; Narasimhan P Agaram; Sally E Trabucco; Victoria Robinson; Richard A Ferraro; Sherri Z Millis; Anita Krishnan; Jessica Lee; Steven Attia; Wassim Abida; Alexander Drilon; Ping Chi; Sandra P D' Angelo; Mark A Dickson; Mary Lou Keohan; Ciara M Kelly; Mark Agulnik; Sant P Chawla; Edwin Choy; Rashmi Chugh; Christian F Meyer; Parvathi A Myer; Jessica L Moore; Ross A Okimoto; Raphael E Pollock; Vinod Ravi; Arun S Singh; Neeta Somaiah; Andrew J Wagner; John H Healey; Garrett M Frampton; Jeffrey M Venstrom; Jeffrey S Ross; Marc Ladanyi; Samuel Singer; Murray F Brennan; Gary K Schwartz; Alexander J Lazar; David M Thomas; Robert G Maki; William D Tap; Siraj M Ali; Dexter X Jin Journal: Nat Commun Date: 2022-06-15 Impact factor: 17.694
Authors: Erica V Carballo; Tra V Pham; Gulisa Turashvili; Krisztina Hanley; Kristen D Starbuck; Jane L Meisel Journal: Gynecol Oncol Rep Date: 2022-08-17